{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:19:25Z","timestamp":1766747965541,"version":"3.43.0"},"reference-count":123,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780443235917"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005639","name":"Universidade de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005639","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.irn.2024.04.015","type":"book-chapter","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T16:33:08Z","timestamp":1719678788000},"page":"65-93","source":"Crossref","is-referenced-by-count":5,"title":["A journey through cannabidiol in Parkinson\u2019s disease"],"prefix":"10.1016","member":"78","reference":[{"issue":"3","key":"10.1016\/bs.irn.2024.04.015_bib1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/WNF.0000000000000550","article-title":"Medical cannabis in the treatment of Parkinson\u2019s disease","volume":"46","author":"Aladeen","year":"2023","journal-title":"Clinical Neuropharmacology"},{"issue":"3\u20134","key":"10.1016\/bs.irn.2024.04.015_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1155\/2004\/516302","article-title":"Parkinson\u2019s disease protects against smoking?","volume":"15","author":"Allam","year":"2004","journal-title":"Behavioural Neurology"},{"issue":"11 Suppl 6","key":"10.1016\/bs.irn.2024.04.015_bib3","first-page":"S51","article-title":"Caffeinated clues from epidemiology of Parkinson\u2019s disease","volume":"61","author":"Ascherio","year":"2003","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/bs.irn.2024.04.015_bib4","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.3390\/ijms21176235","article-title":"Distinctive evidence involved in the role of endocannabinoid signalling in Parkinson\u2019s disease: A perspective on associated therapeutic interventions","volume":"21","author":"Behl","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.irn.2024.04.015_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.989717","article-title":"Cannabidiol for neurodegenerative disorders: A comprehensive review","volume":"13","author":"Bhunia","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"2","key":"10.1016\/bs.irn.2024.04.015_bib6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1006\/bbrc.1999.0254","article-title":"Brain regional distribution of endocannabinoids: Implications for their biosynthesis and biological function","volume":"256","author":"Bisogno","year":"1999","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"2","key":"10.1016\/bs.irn.2024.04.015_bib7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","article-title":"The genetic architecture of Parkinson\u2019s disease","volume":"19","author":"Blauwendraat","year":"2020","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2024.04.015_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiology of Aging"},{"issue":"11","key":"10.1016\/bs.irn.2024.04.015_bib9","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.3390\/molecules26113245","article-title":"Neuroprotection with the cannabidiol quinone derivative VCE-004.8 (EHP-101) against 6-hydroxydopamine in cell and murine models of Parkinson\u2019s disease","volume":"26","author":"Burgaz","year":"2021","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"3","key":"10.1016\/bs.irn.2024.04.015_bib10","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: From overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death & Disease"},{"issue":"1607","key":"10.1016\/bs.irn.2024.04.015_bib11","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders","volume":"367","author":"Campos","year":"2012","journal-title":"Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences"},{"issue":"20","key":"10.1016\/bs.irn.2024.04.015_bib12","doi-asserted-by":"crossref","first-page":"7895","DOI":"10.1073\/pnas.0511232103","article-title":"Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression","volume":"103","author":"Carrier","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/bs.irn.2024.04.015_bib13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3233\/JAD-130050","article-title":"Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy","volume":"35","author":"Casarejos","year":"2013","journal-title":"Journal of Alzheimer\u2019s Disease: JAD"},{"issue":"7","key":"10.1016\/bs.irn.2024.04.015_bib14","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.3390\/molecules28073271","article-title":"The polypharmacological effects of cannabidiol","volume":"28","author":"Castillo-Arellano","year":"2023","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"5","key":"10.1016\/bs.irn.2024.04.015_bib15","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/jcpt.12179","article-title":"Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson\u2019s disease patients: A case series","volume":"39","author":"Chagas","year":"2014","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"11","key":"10.1016\/bs.irn.2024.04.015_bib16","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881114550355","article-title":"Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: An exploratory double-blind trial","volume":"28","author":"Chagas","year":"2014","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"2","key":"10.1016\/bs.irn.2024.04.015_bib17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mds.20279","article-title":"Impact of the motor complications of Parkinson\u2019s disease on the quality of life","volume":"20","author":"Chapuis","year":"2005","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"key":"10.1016\/bs.irn.2024.04.015_bib18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/bs.irn.2018.08.004","article-title":"Molecular Imaging of the Cannabinoid System in Idiopathic Parkinson\u2019s Disease","volume":"141","author":"Cilia","year":"2018","journal-title":"International review of neurobiology"},{"issue":"Pt 10","key":"10.1016\/bs.irn.2024.04.015_bib19","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/brain\/awu195","article-title":"The modern pre-levodopa era of Parkinson\u2019s disease: Insights into motor complications from sub-Saharan Africa","volume":"137","author":"Cilia","year":"2014","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2024.04.015_bib20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.expneurol.2015.04.007","article-title":"Differential upregulation of the cannabinoid CB\u2082 receptor in neurotoxic and inflammation-driven rat models of Parkinson\u2019s disease","volume":"269","author":"Concannon","year":"2015","journal-title":"Experimental Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2024.04.015_bib21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/00207458608985678","article-title":"Open label evaluation of cannabidiol in dystonic movement disorders","volume":"30","author":"Consroe","year":"1986","journal-title":"The International Journal of Neuroscience"},{"issue":"2","key":"10.1016\/bs.irn.2024.04.015_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.bjp.0705920","article-title":"Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation","volume":"143","author":"Costa","year":"2004","journal-title":"British Journal of Pharmacology"},{"issue":"1\u20133","key":"10.1016\/bs.irn.2024.04.015_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2006.11.006","article-title":"The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain","volume":"556","author":"Costa","year":"2007","journal-title":"European Journal of Pharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2024.04.015_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00406-019-00982-6","article-title":"Is cannabidiol the ideal drug to treat non-motor Parkinson\u2019s disease symptoms?","volume":"269","author":"Crippa","year":"2019","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"1","key":"10.1016\/bs.irn.2024.04.015_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","article-title":"Cannabinoids and the expanded endocannabinoid system in neurological disorders","volume":"16","author":"Cristino","year":"2020","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/bs.irn.2024.04.015_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107808","article-title":"Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson\u2019s disease","volume":"163","author":"Crivelaro do Nascimento","year":"2020","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/bs.irn.2024.04.015_bib27","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1007\/s11064-023-03905-z","article-title":"Cannabidiol recovers dopaminergic neuronal damage induced by reserpine or \u03b1-synuclein in Caenorhabditis elegans","volume":"48","author":"da Cruz Guedes","year":"2023","journal-title":"Neurochemical Research"},{"issue":"1","key":"10.1016\/bs.irn.2024.04.015_bib28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12035-013-8514-7","article-title":"Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: Implications for neuroprotection","volume":"49","author":"da Silva","year":"2014","journal-title":"Molecular Neurobiology"},{"issue":"7","key":"10.1016\/bs.irn.2024.04.015_bib29","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/mds.28577","article-title":"Cannabidiol for rapid eye movement sleep behavior disorder","volume":"36","author":"de Almeida","year":"2021","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"2","key":"10.1016\/bs.irn.2024.04.015_bib30","first-page":"374","article-title":"The effect of cannabidiol for restless legs syndrome\/Willis-Ekbom disease in Parkinson\u2019s disease patients with REM sleep behavior disorder: A","volume":"8","author":"de Almeida","year":"2023","journal-title":"Cannabis and Cannabinoid Research"},{"issue":"2","key":"10.1016\/bs.irn.2024.04.015_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0269881119895536","article-title":"Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson\u2019s disease","volume":"34","author":"de Faria","year":"2020","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"12","key":"10.1016\/bs.irn.2024.04.015_bib32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/syn.21941","article-title":"l-DOPA-induced dyskinesia in Parkinson\u2019s disease: Are neuroinflammation and astrocytes key elements?","volume":"70","author":"Del-Bel","year":"2016","journal-title":"Synapse (New York, N.Y.)"},{"key":"10.1016\/bs.irn.2024.04.015_bib33","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.arr.2017.12.007","article-title":"The genetics of Parkinson disease","volume":"42","author":"Deng","year":"2018","journal-title":"Ageing Research Reviews"},{"key":"10.1016\/bs.irn.2024.04.015_bib34","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3389\/fphar.2016.00370","article-title":"A personal retrospective: Elevating anandamide (AEA) by targeting fatty acid amide hydrolase (FAAH) and the fatty acid binding proteins (FABPs)","volume":"7","author":"Deutsch","year":"2016","journal-title":"Frontiers in Pharmacology"},{"issue":"7","key":"10.1016\/bs.irn.2024.04.015_bib35","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/mds.29447","article-title":"Cognitive safety data from a randomized, double-blind, parallel-group, placebo-controlled phase IIb study of the effects of a cannabidiol and \u03949-tetrahydrocannabinol drug on Parkinson\u2019s disease-related motor symptoms","volume":"38","author":"Domen","year":"2023","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"1","key":"10.1016\/bs.irn.2024.04.015_bib36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41392-023-01353-3","article-title":"Signaling pathways in Parkinson\u2019s disease: molecular mechanisms and therapeutic interventions","volume":"8","author":"Dong-Chen","year":"2023","journal-title":"Signal transduction and targeted therapy"},{"key":"10.1016\/bs.irn.2024.04.015_bib37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nbd.2016.06.013","article-title":"Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action","volume":"94","author":"Dos-Santos-Pereira","year":"2016","journal-title":"Neurobiology of Disease"},{"issue":"3","key":"10.1016\/bs.irn.2024.04.015_bib38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/glia.23738","article-title":"Cannabidiol prevents LPS-induced microglial inflammation by inhibiting ROS\/NF-\u03baB-dependent signaling and glucose consumption","volume":"68","author":"Dos-Santos-Pereira","year":"2020","journal-title":"Glia"},{"issue":"4","key":"10.1016\/bs.irn.2024.04.015_bib39","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson\u2019s disease: A source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1016\/bs.irn.2024.04.015_bib40","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s12640-020-00277-y","article-title":"A comparative in vitro study of the neuroprotective effect induced by cannabidiol, cannabigerol, and their respective acid forms: Relevance of the 5-HT1A receptors","volume":"39","author":"Echeverry","year":"2021","journal-title":"Neurotoxicity Research"},{"issue":"14","key":"10.1016\/bs.irn.2024.04.015_bib41","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","article-title":"Fatty acid-binding proteins (FABPs) are intracellular carriers for \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD)","volume":"290","author":"Elmes","year":"2015","journal-title":"The Journal of Biological Chemistry"},{"issue":"1\u20132","key":"10.1016\/bs.irn.2024.04.015_bib42","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neulet.2006.01.047","article-title":"Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement","volume":"399","author":"Esposito","year":"2006","journal-title":"Neuroscience Letters"},{"issue":"3","key":"10.1016\/bs.irn.2024.04.015_bib43","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.neulet.2006.06.012","article-title":"CB1 receptor selective activation inhibits beta-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons","volume":"404","author":"Esposito","year":"2006","journal-title":"Neuroscience Letters"},{"issue":"12","key":"10.1016\/bs.irn.2024.04.015_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028668","article-title":"Cannabidiol reduces A\u03b2-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR\u03b3 involvement","volume":"6","author":"Esposito","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/bs.irn.2024.04.015_bib45","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1476-5381.2008.00088.x","article-title":"The endocannabinoid system as a target for the treatment of motor dysfunction","volume":"156","author":"Fern\u00e1ndez-Ruiz","year":"2009","journal-title":"British Journal of Pharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2024.04.015_bib46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/syn.20047","article-title":"Immunolocalization of CB1 receptor in rat striatal neurons: A confocal microscopy study","volume":"53","author":"Fusco","year":"2004","journal-title":"Synapse (New York, N. Y.)"},{"issue":"13","key":"10.1016\/bs.irn.2024.04.015_bib47","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/bph.13215","article-title":"Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia","volume":"173","author":"Garc\u00eda","year":"2016","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2024.04.015_bib48","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.brainres.2006.11.063","article-title":"Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson\u2019s disease: Importance of antioxidant and cannabinoid receptor-independent properties","volume":"1134","author":"Garc\u00eda-Arencibia","year":"2007","journal-title":"Brain Research"},{"key":"10.1016\/bs.irn.2024.04.015_bib49","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3389\/fphar.2017.00391","article-title":"Cannabidiol is a potential therapeutic for the affective-motivational dimension of incision pain in rats","volume":"8","author":"Genaro","year":"2017","journal-title":"Frontiers in pharmacology"},{"key":"10.1016\/bs.irn.2024.04.015_bib50","article-title":"Segregation of D1 and D2 dopamine receptors in the striatal direct and indirect pathways: An historical perspective","volume":"14","author":"Gerfen","year":"2022","journal-title":"Frontiers in Synaptic Neuroscience"},{"issue":"4","key":"10.1016\/bs.irn.2024.04.015_bib51","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/7268","article-title":"Dopamine activation of endogenous cannabinoid signaling in dorsal striatum","volume":"2","author":"Giuffrida","year":"1999","journal-title":"Nature Neuroscience"},{"issue":"16","key":"10.1016\/bs.irn.2024.04.015_bib52","doi-asserted-by":"crossref","first-page":"8920","DOI":"10.3390\/ijms22168920","article-title":"Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson\u2019s Disease","volume":"22","author":"Giuliano","year":"2021","journal-title":"International journal of molecular sciences"},{"issue":"14","key":"10.1016\/bs.irn.2024.04.015_bib53","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1523\/JNEUROSCI.17-14-05327.1997","article-title":"Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor","volume":"17","author":"Glass","year":"1997","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/bs.irn.2024.04.015_bib54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pnpbp.2013.06.005","article-title":"Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice","volume":"46","author":"Gomes","year":"2013","journal-title":"Progress in Neuro-psychopharmacology & Biological Psychiatry"},{"issue":"7","key":"10.1016\/bs.irn.2024.04.015_bib55","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.euroneuro.2018.04.004","article-title":"Probing the endocannabinoid system in healthy volunteers: Cannabidiol alters fronto-striatal resting-state connectivity","volume":"28","author":"Grimm","year":"2018","journal-title":"European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.04.015_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.fitote.2020.104553","article-title":"Cannabidiol exerts protective effects in an in vitro model of Parkinson\u2019s disease activating AKT\/mTOR pathway","volume":"143","author":"Gugliandolo","year":"2020","journal-title":"Fitoterapia"},{"issue":"6","key":"10.1016\/bs.irn.2024.04.015_bib57","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0200-17.2017","article-title":"A common function of basal ganglia-cortical circuits subserving speed in both motor and cognitive domains","volume":"4","author":"Hanakawa","year":"2017","journal-title":"eNeuro"},{"issue":"3","key":"10.1016\/bs.irn.2024.04.015_bib58","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/can.2020.0105","article-title":"The effects of cannabinoids on pro- and anti-inflammatory cytokines: A systematic review of in vivo studies","volume":"6","author":"Henshaw","year":"2021","journal-title":"Cannabis and Cannabinoid Research"},{"issue":"2","key":"10.1016\/bs.irn.2024.04.015_bib59","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991","article-title":"Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study","volume":"11","author":"Herkenham","year":"1991","journal-title":"The Journal of Neuroscience"},{"issue":"5","key":"10.1016\/bs.irn.2024.04.015_bib60","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bph.13368","article-title":"Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPAR\u03b3 and 5-HT1A receptors","volume":"173","author":"Hind","year":"2016","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1016\/bs.irn.2024.04.015_bib61","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0733-8619(18)30213-5","article-title":"The natural history of Parkinson\u2019s disease in the pre-levodopa and post-levodopa eras","volume":"10","author":"Hoehn","year":"1992","journal-title":"Neurologic Clinics"},{"issue":"1","key":"10.1016\/bs.irn.2024.04.015_bib62","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/(SICI)1098-2396(200007)37:1<71::AID-SYN8>3.0.CO;2-K","article-title":"Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: A double-label in situ hybridization study","volume":"37","author":"Hohmann","year":"2000","journal-title":"Synapse (New York, N. Y.)"},{"issue":"3\u20134","key":"10.1016\/bs.irn.2024.04.015_bib63","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000113678","article-title":"Basic research on dopamine in Parkinson\u2019s disease and the discovery of the nigrostriatal dopamine pathway: The view of an eyewitness","volume":"5","author":"Hornykiewicz","year":"2008","journal-title":"Neuro-Degenerative Diseases"},{"issue":"1","key":"10.1016\/bs.irn.2024.04.015_bib64","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1038\/s41467-023-39307-6","article-title":"Cannabidiol inhibits Nav channels through two distinct binding sites","volume":"14","author":"Huang","year":"2023","journal-title":"Nature Communications"},{"issue":"11","key":"10.1016\/bs.irn.2024.04.015_bib65","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1021\/cn5000524","article-title":"Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: Potential for the treatment of neuronal hyperexcitability","volume":"5","author":"Iannotti","year":"2014","journal-title":"ACS Chemical Neuroscience"},{"issue":"3","key":"10.1016\/bs.irn.2024.04.015_bib66","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3390\/cells10030586","article-title":"The endocannabinoid system and PPARs: Focus on their signalling crosstalk, action and transcriptional regulation","volume":"10","author":"Iannotti","year":"2021","journal-title":"Cells"},{"issue":"6","key":"10.1016\/bs.irn.2024.04.015_bib67","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s12640-023-00671-2","article-title":"Effect of cannabidiol in LPS-induced toxicity in astrocytes: Possible role for cannabinoid type-1 receptors","volume":"41","author":"Ibork","year":"2023","journal-title":"Neurotoxicity Research"},{"issue":"1","key":"10.1016\/bs.irn.2024.04.015_bib68","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1471-4159.2003.02327.x","article-title":"Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells","volume":"89","author":"Iuvone","year":"2004","journal-title":"Journal of Neurochemistry"},{"year":"2010","series-title":"Dopamine handbook","author":"Iversen","key":"10.1016\/bs.irn.2024.04.015_bib69"},{"issue":"1","key":"10.1016\/bs.irn.2024.04.015_bib70","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0306-4522(03)00070-8","article-title":"Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia","volume":"119","author":"Julian","year":"2003","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/bs.irn.2024.04.015_bib71","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12640-019-00109-8","article-title":"Cannabidiol and cannabinoid compounds as potential strategies for treating Parkinson\u2019s disease and L-DOPA-induced dyskinesia","volume":"37","author":"Junior","year":"2020","journal-title":"Neurotoxicity Research"},{"issue":"5","key":"10.1016\/bs.irn.2024.04.015_bib72","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/ane.12563","article-title":"The genetic background of Parkinson\u2019s disease: Current progress and future prospects","volume":"134","author":"Kalinderi","year":"2016","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1016\/bs.irn.2024.04.015_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.654340","article-title":"Cannabidiol induces autophagy to protects neural cells from mitochondrial dysfunction by upregulating SIRT1 to inhibits NF-\u03baB and NOTCH pathways","volume":"15","author":"Kang","year":"2021","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/bs.irn.2024.04.015_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.970714","article-title":"Parkinson\u2019s disease, dopaminergic drugs and the plant world","volume":"13","author":"Kempster","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"7128","key":"10.1016\/bs.irn.2024.04.015_bib75","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nature05506","article-title":"Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson\u2019s disease models","volume":"445","author":"Kreitzer","year":"2007","journal-title":"Nature"},{"issue":"20","key":"10.1016\/bs.irn.2024.04.015_bib76","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"British Journal of Pharmacology"},{"issue":"1\u20132","key":"10.1016\/bs.irn.2024.04.015_bib77","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.nbd.2004.11.009","article-title":"Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson\u2019s disease","volume":"19","author":"Lastres-Becker","year":"2005","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/bs.irn.2024.04.015_bib78","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cca.2021.08.009","article-title":"Dopamine in Parkinson\u2019s disease","volume":"522","author":"Latif","year":"2021","journal-title":"Clinica Chimica Acta; International Journal of Clinical Chemistry"},{"issue":"4","key":"10.1016\/bs.irn.2024.04.015_bib79","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1089\/can.2019.0068","article-title":"Safety and tolerability of cannabidiol in Parkinson disease: An open label, dose-escalation study","volume":"5","author":"Leehey","year":"2020","journal-title":"Cannabis and Cannabinoid Research"},{"issue":"9680","key":"10.1016\/bs.irn.2024.04.015_bib80","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","article-title":"Parkinson\u2019s disease","volume":"373","author":"Lees","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/bs.irn.2024.04.015_bib81","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","article-title":"An introduction to the endogenous cannabinoid system","volume":"79","author":"Lu","year":"2016","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1016\/bs.irn.2024.04.015_bib82","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ajpath.2015.09.023","article-title":"Dopaminergic neurons and brain reward pathways: From neurogenesis to circuit assembly","volume":"186","author":"Luo","year":"2016","journal-title":"The American Journal of Pathology"},{"issue":"1","key":"10.1016\/bs.irn.2024.04.015_bib83","doi-asserted-by":"crossref","first-page":"6632","DOI":"10.1038\/s41467-023-42416-x","article-title":"Ligand activation mechanisms of human KCNQ2 channel","volume":"14","author":"Ma","year":"2023","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/bs.irn.2024.04.015_bib84","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1006\/exnr.1997.6645","article-title":"The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson\u2019s disease","volume":"148","author":"Maneuf","year":"1997","journal-title":"Experimental Neurology"},{"issue":"11","key":"10.1016\/bs.irn.2024.04.015_bib85","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1021\/acschemneuro.3c00176","article-title":"Cannabidiol protects dopaminergic-like neurons against paraquat- and maneb-induced cell death through safeguarding DJ-1CYS106 and caspase 3 independently of cannabinoid receptors: Relevance in Parkinson\u2019s disease","volume":"14","author":"Mendivil-Perez","year":"2023","journal-title":"ACS Chemical Neuroscience"},{"issue":"22","key":"10.1016\/bs.irn.2024.04.015_bib86","doi-asserted-by":"crossref","first-page":"8870","DOI":"10.3390\/ijms21228870","article-title":"Cannabidiol for pain treatment: Focus on pharmacology and mechanism of action","volume":"21","author":"Mlost","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"8\u20139","key":"10.1016\/bs.irn.2024.04.015_bib87","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.phymed.2012.04.002","article-title":"Effects of cannabinoids \u0394(9)-tetrahydrocannabinol, \u0394(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures","volume":"19","author":"Moldzio","year":"2012","journal-title":"Phytomedicine: International Journal of Phytotherapy and Phytopharmacology"},{"key":"10.1016\/bs.irn.2024.04.015_bib88","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1353-8020(11)70883-5","article-title":"Phytocannabinoids tetrahydrocannabinol and cannabidiol act against rotenone induced damages in murine cell cultures","volume":"18","author":"Moldzio","year":"2012","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1016\/bs.irn.2024.04.015_bib89","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13024-015-0012-0","article-title":"Promising cannabinoid-based therapies for Parkinson\u2019s disease: Motor symptoms to neuroprotection","volume":"10","author":"More","year":"2015","journal-title":"Molecular Neurodegeneration"},{"key":"10.1016\/bs.irn.2024.04.015_bib90","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.neuro.2022.09.001","article-title":"Neuroprotective effects of cannabidiol on dopaminergic neurodegeneration and \u03b1-synuclein accumulation in C. elegans models of Parkinson\u2019s disease","volume":"93","author":"Muhammad","year":"2022","journal-title":"Neurotoxicology"},{"key":"10.1016\/bs.irn.2024.04.015_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1294420","article-title":"The complex relationship between obesity and neurodegenerative diseases: An updated review","volume":"17","author":"Neto","year":"2023","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"1","key":"10.1016\/bs.irn.2024.04.015_bib92","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s42238-023-00186-9","article-title":"The therapeutic potential of purified cannabidiol","volume":"5","author":"O\u2019Sullivan","year":"2023","journal-title":"Journal of Cannabis Research"},{"key":"10.1016\/bs.irn.2024.04.015_bib93","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/425289","article-title":"Time-dependent vascular effects of Endocannabinoids mediated by peroxisome proliferator-activated receptor gamma (PPAR\u03b3)","volume":"2009","author":"O\u2019Sullivan","year":"2009","journal-title":"PPAR Research"},{"key":"10.1016\/bs.irn.2024.04.015_bib94","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1146\/annurev-pharmtox-010818-021441","article-title":"Beyond THC and endocannabinoids","volume":"60","author":"Pacher","year":"2020","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"3","key":"10.1016\/bs.irn.2024.04.015_bib95","first-page":"313","article-title":"Substantia nigra and Parkinson\u2019s disease: A brief history of their long and intimate relationship","volume":"37","author":"Parent","year":"2010","journal-title":"The Canadian Journal of Neurological"},{"issue":"2","key":"10.1016\/bs.irn.2024.04.015_bib96","first-page":"222","article-title":"An essay on the shaking palsy","volume":"14","author":"Parkinson","year":"1817","journal-title":"The Journal of Neuropsychiatry and Clinical Neurosciences"},{"key":"10.1016\/bs.irn.2024.04.015_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.945836","article-title":"Intrapallidal injection of cannabidiol or a selective GPR55 antagonist decreases motor asymmetry and improves fine motor skills in hemiparkinsonian rats","volume":"13","author":"Patricio","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/bs.irn.2024.04.015_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.595635","article-title":"Cannabidiol as a therapeutic target: Evidence of its neuroprotective and neuromodulatory function in Parkinson\u2019s disease","volume":"11","author":"Patricio","year":"2020","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/bs.irn.2024.04.015_bib99","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neuropharm.2013.03.027","article-title":"Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT(1 A) and CB2 receptors","volume":"71","author":"Pazos","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2024.04.015_bib100","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fphar.2016.00343","article-title":"Cannabidiol prevents motor and cognitive impairments induced by reserpine in rats","volume":"7","author":"Peres","year":"2016","journal-title":"Frontiers in Pharmacology"},{"issue":"6","key":"10.1016\/bs.irn.2024.04.015_bib101","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tins.2021.02.001","article-title":"Modulating the neuromodulators: Dopamine, serotonin, and the endocannabinoid system","volume":"44","author":"Peters","year":"2021","journal-title":"Trends in Neurosciences"},{"issue":"2","key":"10.1016\/bs.irn.2024.04.015_bib102","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/mds.23457","article-title":"Homeostatic changes of the endocannabinoid system in Parkinson\u2019s disease","volume":"26","author":"Pisani","year":"2011","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"8","key":"10.1016\/bs.irn.2024.04.015_bib103","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","article-title":"Prevention of Alzheimer\u2019s disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation","volume":"25","author":"Ram\u00edrez","year":"2005","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"5","key":"10.1016\/bs.irn.2024.04.015_bib104","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/sj.bjp.0705467","article-title":"Anandamide and vanilloid TRPV1 receptors","volume":"140","author":"Ross","year":"2003","journal-title":"British Journal of Pharmacology"},{"issue":"8","key":"10.1016\/bs.irn.2024.04.015_bib105","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochemical Research"},{"issue":"7","key":"10.1016\/bs.irn.2024.04.015_bib106","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1523\/JNEUROSCI.4212-08.2009","article-title":"Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels","volume":"29","author":"Ryan","year":"2009","journal-title":"The Journal of Neuroscience"},{"issue":"7","key":"10.1016\/bs.irn.2024.04.015_bib107","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"British Journal of Pharmacology"},{"issue":"1 Pt B","key":"10.1016\/bs.irn.2024.04.015_bib108","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.tiv.2015.11.004","article-title":"The neuroprotection of cannabidiol against MPP\u207a-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson\u2019s disease","volume":"30","author":"Santos","year":"2015","journal-title":"Toxicology In Vitro: An International Journal Published in Association with BIBRA"},{"issue":"1","key":"10.1016\/bs.irn.2024.04.015_bib109","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12035-014-8843-1","article-title":"Cannabidiol exposure during neuronal differentiation sensitizes cells against redox-active neurotoxins","volume":"52","author":"Sch\u00f6nhofen","year":"2015","journal-title":"Molecular Neurobiology"},{"issue":"10","key":"10.1016\/bs.irn.2024.04.015_bib110","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.195","article-title":"Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose","volume":"6","author":"Seeman","year":"2016","journal-title":"Translational Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/bs.irn.2024.04.015_bib111","first-page":"201","article-title":"Beneficial and adverse effects of cannabidiol in a Parkinson patient with sinemet-induced dystonic dyskinesia","volume":"35","author":"Snider","year":"1985","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2024.04.015_bib112","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbr.2016.04.042","article-title":"Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice","volume":"309","author":"Sonego","year":"2016","journal-title":"Behavioural Brain Research"},{"issue":"1","key":"10.1016\/bs.irn.2024.04.015_bib113","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/can.2017.0002","article-title":"Cannabinoids in Parkinson\u2019s disease","volume":"2","author":"Stampanoni Bassi","year":"2017","journal-title":"Cannabis and Cannabinoid Research"},{"key":"10.1016\/bs.irn.2024.04.015_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fnsyn.2023.1186484","article-title":"Rethinking the network determinants of motor disability in Parkinson\u2019s disease","volume":"15","author":"Surmeier","year":"2023","journal-title":"Frontiers in Synaptic Neuroscience"},{"issue":"2","key":"10.1016\/bs.irn.2024.04.015_bib115","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1684\/ecn.2020.0445","article-title":"Natural cannabinoids suppress the cytokine storm in sepsis-like in vitro model","volume":"31","author":"Szekely","year":"2020","journal-title":"European Cytokine Network"},{"issue":"5","key":"10.1016\/bs.irn.2024.04.015_bib116","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"British journal of pharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2024.04.015_bib117","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2169\/internalmedicine.52.8333","article-title":"Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson\u2019s disease","volume":"52","author":"Utsumi","year":"2013","journal-title":"Internal Medicine (Tokyo, Japan)"},{"issue":"1","key":"10.1016\/bs.irn.2024.04.015_bib118","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000527335","article-title":"Cannabis sativa and cannabidiol: A therapeutic strategy for the treatment of neurodegenerative diseases?","volume":"5","author":"Viana","year":"2022","journal-title":"Medical Cannabis and Cannabinoids"},{"key":"10.1016\/bs.irn.2024.04.015_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108700","article-title":"Cannabidiol has therapeutic potential for myofascial pain in female and male parkinsonian rats","volume":"196","author":"Vivanco-Estela","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2024.04.015_bib120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.neuroscience.2022.06.036","article-title":"Cannabidiol alleviates the damage to dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson\u2019s disease mice via regulating neuronal apoptosis and neuroinflammation","volume":"498","author":"Wang","year":"2022","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/bs.irn.2024.04.015_bib121","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1213\/ANE.0b013e3182283486","article-title":"Cannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 mice","volume":"113","author":"Ward","year":"2011","journal-title":"Anesthesia and Analgesia"},{"key":"10.1016\/bs.irn.2024.04.015_bib122","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.freeradbiomed.2018.06.023","article-title":"Cannabidiol induced apoptosis in human monocytes through mitochondrial permeability transition pore-mediated ROS production","volume":"124","author":"Wu","year":"2018","journal-title":"Free Radical Biology & Medicine"},{"issue":"8","key":"10.1016\/bs.irn.2024.04.015_bib123","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/0269881108096519","article-title":"Cannabidiol for the treatment of psychosis in Parkinson\u2019s disease","volume":"23","author":"Zuardi","year":"2009","journal-title":"Journal of Psychopharmacology (Oxford, England)"}],"container-title":["International Review of Neurobiology","Cannabidiol in Neurology and Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774224000679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774224000679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T15:53:12Z","timestamp":1754409192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774224000679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443235917"],"references-count":123,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2024.04.015","relation":{},"ISSN":["0074-7742"],"issn-type":[{"type":"print","value":"0074-7742"}],"subject":[],"published":{"date-parts":[[2024]]}}}